The Youtube Apocalypse: The Good, The Bad, The Ugly

Source: CanadianPrepper
April 15, 2017

I discuss the reasons for the youtube creator adsense apocalypse and how demonetization may be incentive for those channels to get out of their comfort zone and start seeking sponsorships.

Monopoly concerns over AT&T and Time Warner mega-merger

Source: RT
October 25, 2016

Telecommunications company AT&T has agreed to purchase the content division of Time Warner for $85 billion. There are concerns that the deal between the two mega companies will create a monopoly. RT America’s Manila Chan has the latest on the deal and why some object to it.

Bayer raises bid to purchase Monsanto to over $65 BILLION

Monsanto

Source: NaturalNews.com
Vicki Batts
September 13, 2016

German pharmaceutical giant Bayer AG seems to know no limits in its quest to acquire the world’s most notorious agricultural company. The drug manufacturer has recently pushed its offer for procuring Monsanto up to a whopping $65 billion.

Bayer has confirmed that the two corporations are currently engaged in “advanced negotiations,” though it seems less like negotiating and more like Monsanto trying to take Bayer for everything they have. The original offer from Bayer averaged out to $122 per share, or $62 billion. Their new $65 billion offer averages out to about $127.50 per share. Bayer would also assume Monsanto’s $9 billion in debt, which pushes their offer up by an additional 2 percent. However, Monsanto is apparently seeking a jaw-dropping $130 per share, at least according to Bloomberg.

The attempted wooing of Monsanto is just one of many consolidations that have occurred lately in the agricultural industry. Bloomberg reports, “China National Chemical Corp. agreed in February to acquire Syngenta AG, while DuPont Co. and Dow Chemical Co. plan to merge and then carve out a new crop-science unit.” These kinds of deals in the crop and seed industry threaten to leave just a few oversized global giants in the Big Ag industrial complex.

If Bayer and Monsanto were to merge, they would create what would be one of the world’s largest agricultural suppliers. Monsanto is presently the world’s largest seed manufacturer, and Bayer currently offers their own “crop-protection” products (if you can really call them that). Between the two, they will make for a nearly-untouchable conglomerate. Monsanto has announced that it is considering Bayer’s offer, but the company is not the GMO giant’s only suitor; several other companies are seeking to acquire Monsanto as well.

In spite of their tremendous offer, Monsanto reportedly feels that their company is somehow being undervalued, but is still “open” to negotiation. Clearly, Monsanto is blind to the growing aversion to its name and products.

While the apparent ego of the company is worrisome, there are many more things to be concerned about, especially if this deal were to come to fruition. If two massive companies tied to the agricultural industry join forces, it could spell disaster for farmers and food prices. Their consolidation would lead to fewer choices for farmers, and you know what happens when there is a monopoly: prices skyrocket. With farmer bargaining power limited, it’s natural to expect seed prices to increase. And that means that the price of produce in supermarkets will increase along with them.

Robert Lawrence, a professor from Johns Hopkins School of Medicine and the founding director of the Center for a Liveable Future, told Market Watch, “The consolidation and driving out of smaller competitors, and controlling the marketplace and raising prices of seeds and pesticides for farmers worldwide is going to be a real shock to the food system.”

The merger could also mean fewer options for consumers, and may even effect the availability of organic crops and crops grown with fewer pesticides. Given the size of the two companies, the potential for them to further reduce farmers’ options is very real.

You would think that with the growing demand for organic, pesticide-free produce, Bayer would not be so interested in Monsanto; after all, that name has become something of a dirty word.

However, Bayer reportedly took Monsanto’s poor image into account, but made their offer to acquire the company anyway. This isn’t surprising though; anytime two large companies such as these merge together, the net result will always be more power. Even if people don’t like them, the increase in market share will still inevitably yield more economic power. And with economic power comes political power. As if Monsanto doesn’t already have their claws deep enough into our political system, merging with Bayer would surely grant them invincibility.

The most frightening thing about this acquisition is its potential to make Monsanto a stronger force in the agricultural industry, and consequently, further reduce the availability of non-GMO foods.

Read More At: NaturalNews.com

Sources:

USAToday.com

Bloomberg.com


MarketWatch.com

Harvard Study Finally Admits Drug Prices are High Because Govt Grants Big Pharma a Monopoly

big-pharma
via: GreyEnigma.wordpress.com
via: SentinalBlog.com
Source: ActivistPost.com
Matt Agorist
August 27, 2016

In what can only be described as paradigm-shattering research on drug prices, the Journal of the American Medical Association has officially recognized why drug prices skyrocket in America. Big pharma is granted a monopoly by the State which effectively eliminates their competition and allows them to charge any price they want — so they do.

The new paper, published on August 23,  “The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” set out to  “review the origins and effects of high drug prices in the US market and to consider policy options that could contain the cost of prescription drugs.”

What the paper’s authors, Harvard Medical School doctors Aaron Kesselheim and Jerry Avorn, and jurist Ameet Sarpatwari, found and subsequently admitted, shatters the very assertion that government regulation in the market is needed to keep medical care costs low. In fact, their findings were quite to the contrary.

According to the paper:

The most important factor that allows manufacturers to set high drug prices is market exclusivity, protected by monopoly rights awarded upon Food and Drug Administration approval and by patents.

Imagine that.

The costs associated with studying, testing, and getting new drugs approved can be staggering, and the money made from selling the new drug is often used to pay for future drugs as well as paying back investments made to produce the current ones. Unfortunately, the people involved in creating life-saving drugs cannot work for free.

Nothing is wrong with making a drug that saves lives and profiting from it. However, when the profits are a direct result of government involvement, it no longer becomes an issue of innovation and the market, but rather an issue of a State-granted monopoly.

According to the paper:

Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices; rather, prescription drugs are priced in the United States primarily on the basis of what the market will bear.

Increasing the market price of an item to the maximum profit per unit is a natural function of the free market. And, contrary to what the pro-government regulation sect asserts, this increase in price in relation to supply coupled with competition, happens to work toward keeping prices down — unless these prices are protected by a government-granted monopoly. 

As the paper points out:

The most important factor that allows manufacturers to set high drug prices for brand-name drugs is market exclusivity, which arises from 2 forms of legal protection against competition. Together, these factors generate government-granted monopoly rights for a defined period. Initial regulatory exclusivity is awarded at FDA approval.

While the Journal of the American Medical Association is finally admitting the reason for skyrocketing drug prices, Austrian economists have been pointing this out for decades.

Ludwig von Mises correctly explains the situation in the statement below:

As has been pointed out already, there is no such tendency toward monopolization. It is a fact that with many commodities in many countries monopoly prices prevail, and moreover, some articles are sold at monopoly prices on the world market. However, almost all of these instances of monopoly prices are the outgrowth of government interference with business. They were not created by the interplay of the factors operating on a free market. They are not products of capitalism, but precisely of the endeavors to counteract the forces determining the height of the market prices. It is a distortion of fact to speak of monopoly capitalism. It would be more appropriate to speak of monopoly interventionism or of monopoly statism.

A glaring example of the staggering discrepancies in American drug prices can be seen in the remarkable drug for Hep C, sofosbuvir. Sofosbuvir boasts a near miraculous cure rate of 84-96% for Hep C. 

However, the American version of the drug Solvaldi by Gilead, which has an FDA-granted monopoly protecting it, will cost patients a mountainous $84,000. 

In India, however, Gilead has to compete in a free market. Competitors, of which there a many, using the older, much cheaper, and equally effective drug, have driven the price down to a mere $4 a pill. This makes the total cost of curing Hepatitis C in India’s free market — $336.

Because the FDA has become little more than a revolving door for the pharmaceutical industry to continually grant itself special privilege, the natural checks and balances of the market do not apply and we see seemingly insane price differences when compared to other markets.

One example of this revolving door is FDA member, Milton Packer, who chairs the Cardiovascular and Renal Drugs Advisory Committee. Packer, who reviews applications for drugs submitted for FDA approval, is financed by Novartis and actually spoke on their behalf to the advisory board that he chaired.

According to the Wall Street Journal, Packer also appeared before the Cardiovascular and Renal Drugs Advisory Committee involved speaking on behalf of Bristol-Myers Squibb in 2002; acted as a consultant and speaker for GlaxoSmithKline in 2003; appeared as a speaker for NitroMed in 2005; appeared as a speaker for Sanofi in 2009 and acted as a consultant on behalf of Pfizer in 2010.

And Packer is only one example, the list goes on.

The timing of this paper is impeccable given the recent hoopla in the news on the absurd price hike of EpiPens. Mylan CEO, Heather Bresch – daughter of Senator Joe Manchin (D-West Virginia) — is on the receiving end of the FDA’s power to monopolize drugs. As a result of her monopoly, no one can compete with Mylan which has grown Bresch’s annual salary from $2.4 million in 2007 to $18.9 million in 2015.

Again, there is nothing wrong with making money. But, when that money is made at the expense of everyone else — freedom loses.

While the mainstream media often acknowledges that these drug companies charge exorbitant prices for their medications, they conveniently leave out the reason they can do so is because they have the full support of Uncle Sam.

Instead of looking at the corrupt government, who has the unique ability to create and sustain monopolies, the evil market is blamed, and people ironically call for more government – thus creating a vicious cycle of corporatism.

Hopefully, this admonition in JAMA, by these doctors from the Harvard Medical School, opens the eyes of those who continuously cry for more regulation to control prices. We’ve seen where that’s gotten us.

Here at the Free Thought Project we agree with the authors when they say:

High drug prices are the result of the approach the United States has taken to granting government-protected monopolies to drug manufacturers, combined with coverage requirements imposed on government-funded drug benefits. The most realistic short-term strategies to address high prices include enforcing more stringent requirements for the award and extension of exclusivity rights; enhancing competition by ensuring timely generic drug availability.

Matt Agorist is the co-founder of TheFreeThoughtProject.com, where this article first appeared. He is an honorably discharged veteran of the USMC and former intelligence operator directly tasked by the NSA. This prior experience gives him unique insight into the world of government corruption and the American police state. Agorist has been an independent journalist for over a decade and has been featured on mainstream networks around the world.

Read More At: GreyEnigma.com